medigraphic.com
ISSN 0188-9796 (Impreso)

2006, Número 3

<< Anterior Siguiente >>

Rev Endocrinol Nutr 2006; 14 (3)


Diabetes mellitus (DM), menopausia y reemplazo hormonal

Garay-Sevilla ME, Arellano S, Espinosa CJJ

Idioma: Español
Referencias bibliográficas: 38
Paginas: 191-195
Archivo PDF: 74.68 Kb.


FRAGMENTO

La DM es un grupo de enfermedades metabólicas (trastornos del metabolismo de los hidratos de carbono, grasas y proteínas) caracterizadas por defectos en la secreción y la acción de la insulina, lo que conduce a hiperglucemia. Cuando ésta es crónica causa daño a largo plazo, con disfunción e insuficiencia de varios órganos tanto por microangiopatía principalmente en ojos, riñones y nervios, como por macroangiopatía, manifiesta en corazón y vasos sanguíneos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27(supp 1): 5S-10S.

  2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care 1998; 21: 1414-1431.

  3. Secretaría de Salud. Dirección de Epidemiología. México 2006.

  4. Malacara JM, Canto T, Bassol S, Gonzalez N, Cacique L, Vera ML, Nava LE. Symtoms at pre-and postmenopause in rural and urban women from three states of Mexico. Maturitas 2002; 43: 11-19.

  5. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, M- Taskinen R, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.

  6. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Gemma L, Santi L, Bonadonna RC, Muggeo M. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data fron the Verona Diabetes Complications Study. Diabetic Medicine 2003; 21: 52-58.

  7. Grundy SM, Hansen B, Smith, SC Jr, Cleeman, JI, Kahn, RA, for Conference Participants. Clinical management of metabolic syndrome. Circulation 2004; 109: 551.

  8. Jacobson TA, Case CC, Roberts S, Buckley A, Murtaugh KM, Sung JCY, Gause D, Varas C, Ballantyne CM. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes, Obesity, and Metabolism 2004; 6: 353-362.

  9. Alberti K, Zimmet P, Jonathan S. The metabolic syndrome: a new worldwide definition. The Lancet 2005; 366: 1059-1062.

  10. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404-2211.

  11. Brandenburg SL, Lindenfeld J, Reusch JE, Regensteiner JG. Cardiovascular risk in women with type 2 diabetes. Medical Clinics of North America 2003; 87: 955-969.

  12. Kjaer K, Hagen C, Sando S, Eshoj O. Epidemiology of menarche and menstrual disturbances in an unselected group of women with insulin-dependent diabetes mellitus compared to control subjects. J Clin Endocrinol Metab 1992; 75: 524-529.

  13. Casson IF, Clarke CA, Howard CV, McKendrick O, Pennycook S, Pharoah PO, Platt MJ, Stanisstreet M, van Velszen D, Walkinshaw S. Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study. BMJ 1997; 315: 275-278.

  14. Dorman JS, Steenkiste AR, Foley TP, Strotmeyer ES, Burke JP, Kuller LH, Kwoh CK. Menopause in Type 1 Diabetic Women: Is it Premature? Diabetes 2001; 50: 1857-1862.

  15. López-López R, Huerta R, Malacara JM. Age at menopause in women with type 2 diabetes mellitus. Menopause 1999; 6: 174-178.

  16. Malacara JM, Huerta R, Rivera B, Esparza S. Menopause in normal and uncomplicated NIDDM women: physical and emotional symptoms and hormone profile. Maturitas 1997; 28: 35-45.

  17. Han TS, Bijnen MEJ, Seidell JC. Separate associations of waist and hip circumference with lifestyle factors. International Journal of Epidemiology 1998; 27: 422-430.

  18. Lloyd CE, Wing RR, Orchard TJ. Waist to hip ratio and psychosocial factors in adults with insulin-dependent diabetes mellitus: The Pittsburg epidemiology and diabetes complications study. Metabolism 1996; 45: 268-272.

  19. Zhang Y, Howard BV, Cowan LD, Yeh J, Schaefer CF, Wild RA, Wang W, Lee ET. The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american indian postmenopausal women: The strong heart study. Diabetes Care 2002; 25: 500-504.

  20. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, Howard BV, for the Women’s Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetología 2004; 47: 1175-1187.

  21. Samaras K, Hayward CS, Sullivan D, Kelly RP, Campbell LV. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. Diabetes Care 1999; 22: 1401-1407.

  22. Ryan AS, Nicklas BJ, Berman DM. Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 2002; 25: 127-133.

  23. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E. Glycemic effects of postmenopausal hormone therapy: The heart and estrogen/progestin replacement study: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 1-9.

  24. Sites CK, L’Hommedieu GD, Toth MJ, Brochu M, Cooper BC, Fairhurst PA. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: A randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005; 90: 2701-2707.

  25. Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the postmenopausal estrogen/progestin intervention trial. J Clin Endocrinol Metab 2003; 88: 1646-1652.

  26. Kim D-J, Barrett-Connor E. Association of serum proinsulin with hormone replacement therapy in nondiabetic older women. The Rancho Bernardo Study. Diabetes Care 2006; 29: 618-624.

  27. Crespo CJ, Smit E, Snelling A, Sempos CT, Andersen RE. Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women. Results from the Third National and Nutrition Examination Survey (NHANES III). Diabetes Care 2002; 25: 1675-1680.

  28. McKenzie J, Jaap AJ, Gallacher S, Kelly A, Crawford L, Greer IA, Rumley A, Petrie JR, Lowe GD, Paterson K, Sattar N. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with diabetes: Potentially safer with respect to vascular risk? Clin Endocrinol 2003; 59: 682-689.

  29. Perera M, Sattar N, Petrie JR, Hillier C, Small M, Connell JMC, Lowe GDO, Lumsden M-A. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endotelial markers in postmenopausal women with type 2 diabetes: A randomized, placebo-controlled study. J Clin Endocrinol Metab 2001; 86: 1140-1143.

  30. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease–related mortality among postmenopausal women who use hormones: Evidence from a national cohort. Am J Obstet Gynecol 1991; 164: 489-494.

  31. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten years follow-up from the Nurse’s Health Study. N Engl J Med 1991; 325: 756-762.

  32. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461.

  33. Newton KM, LaCroix AZ, McKnight B, Knopp RH, Siscovick DS, Heckbert SR, Weiss NS. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol 1997; 145: 269-277.

  34. Grodstein F, Manson JAE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurse’s Health Study. A prospective, observational study. Ann Inter Med 2001; 135: 1-8.

  35. Writing Group for the Women´s Heath Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women´s health initiative randomized controlled trial. JAMA 2002; 288: 321-333.

  36. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, for the Women’s health Initiative Investigators. Estrogens plus progestins and the Coronary Hearth Disease. N Engl J Med 2003; 349: 523-534.

  37. The women’s health initiative steering committee. Effects of conjugated equine estrogens in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701-1712.

  38. Vittinghoff E, Shlipack MG, Varosy PD, Furberg CD, Ireland CC, Khan SS, Blumenthal R, Barrett-Connor E, Hulley S, for the Heart and estrogen/progestin replacement study research group. Risk factors and secondary prevention in women with hearth disease: The hearth and estrogen/progestin replacement study. Ann Inter Med 2003; 138: 81-89.




2020     |     www.medigraphic.com